Market Research Logo

United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)

United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)

Overactive bladder (OAB) syndrome is a chronic medical condition which has a significant impact on the quality of life in a major amount of the population. Overactive bladder is the name given to a group of urinary symptoms that include a strong, uncontrollable urge to urinate at unexpected times, which may result in urine leakage (incontinence), and frequent urination during the day and night. OAB affects performance of daily activities and social functions such as work, traveling, physical exercise, sleep, and sexual function. OAB is a prevalent condition that affects the lives of millions of adults in the US and around the world. An estimated 30 million Americans suffer from overactive bladder, which is uncomfortable, disturbing, and potentially severe.

The treatment approaches for OAB includes behavioral therapy, such as bladder training and pelvic floor exercises. Second line treatment includes pharmacological intervention, historically with anticholinergic medications and more recently with the novel Beta 3 agonist mirabegron. For patients with persistent OAB symptoms, third-line treatment includes procedural therapy using BOTOX injected directly into the bladder to induce temporary muscle paralysis or neuromodulation to enhance neural signals and inhibit reflex detrusor contraction.

The US Overactive Bladder market is set to experience favorable growth driven by factors such rising ageing population, increasing health care expenditure, growing obese population, surging diabetic prevalence and increasing coffee intake. The major trends observed in this market include advancing innovative therapies, increasing awareness for OAB and development of gene therapy. However, the growth of the market is constrained by challenges such as entry of generic drugs in the market, stringent regulations and side effects of oral therapies of OAB.

The report “United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)” analyses the development of the respective market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth.


1. Market Overview
1.1 Overactive Bladder
Table 1: Normal Bladder versus Overactive Bladder
1.2 Symptoms & Diagnosis
1.3 Treatment
Table 2: OAB Treatment Approaches
1.4 Overactive Bladder with BPH
2. US Market Analysis
2.1 Overactive Bladder Market
2.1.1 US Overactive Bladder Market Forecast by Value
Table 3: US Overactive Bladder Market Forecast by Value (2020-2030)
2.1.2 US Overactive Bladder Market by Drug Class
Table 4: The US Overactive Bladder Market by Drug Class (2020/2030)
2.1.3 US Anticholinergics Market Forecast by Value
Table 5: The US Anticholinergics Market Forecast by Value (2020-2030)
2.1.4 US Beta 3 Adrenoreceptor Agonists Market Forecast by Value
Table 6: US Beta 3 Adrenoreceptor Agonists Market Forecast by Value (2020-2030)
2.1.5 US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug
Table 7: US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug (2020/2024/2030)
2.1.6 US Vibegron Drug Revenue Forecast
Table 8: US Vibegron Drug Revenue Forecast (2020-2030)
2.1.7 US Vibegron Prescriptions Volume Forecast
Table 9: US Vibegron Prescriptions Volume Forecast (2020-2030)
2.1.8 US Mirabegron Prescriptions Volume Forecast
Table 10: US Mirabegron Prescriptions Volume Forecast (2020-2030)
2.1.9 US Overactive Bladder Patient Population Forecast
Table 11: US Overactive Bladder Patient Population Forecast (2020-2030)
2.1.10 US Overactive Bladder Treated Patient Population Forecast
Table 12: US Overactive Bladder Treated Patient Population Forecast (2020-2030)
2.1.11 US Overactive Bladder Prescriptions Volume Forecast
Table 13: US Overactive Bladder Prescriptions Volume Forecast (2020-2030)
2.2 Overactive Bladder Market with BPH
2.2.1 US Overactive Bladder with BPH Patient Population Forecast
Table 14: US Overactive Bladder with BPH Patient Population Forecast (2020-2030)
2.2.2 US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate
Table 15: US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate (2020-2030)
2.2.3 US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug
Table 16: US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug (2021/2024/2030)
2.2.4 US Vibegron Drug Revenue Forecast
Table 17: US Vibegron Drug Revenue Forecast (2021-2030)
2.2.5 US Vibegron Prescriptions Volume Forecast
Table 18: US Vibegron Prescriptions Volume Forecast (2021-2030)
2.2.6 US Mirabegron Prescriptions Volume Forecast
Table 19: US Mirabegron Prescriptions Volume Forecast (2021-2030)
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Rising Ageing Population
Table 20: US Ageing Population (65 years & Above) (2013-2017)
3.1.2 Increasing Health Care Expenditure
Table 21: US Healthcare Expenditure; 1990-2020 (%)
3.1.3 Growing Obese Population
Table 22: US Obese Population (20 years & Above) (2008-2017)
3.1.4 Surging Diabetic Prevalence
Table 23: US Diagnosed Diabetic Population (2010-2017)
3.1.5 Increasing Coffee Intake
Table 24: Domestic Consumption of Coffee in US (2014-2018)
3.2 Key Trends & Development
3.2.1 Advancing Innovative Therapies
3.2.2 Rising Awareness for OAB
3.2.3 Development of Gene Therapy
3.3 Challenges
3.3.1 Entry of Generic Drugs
3.3.2 Stringent Regulations
3.3.3 Side Effects of Oral Therapies
4. Competition
4.1 Global Market
4.1.1 Revenue Comparison by Company
Table 25: Revenue Comparison by Company (2017)
4.1.2 Market Cap Comparison by Company
Table 26: Market Cap Comparison by Company (2017)
5. Company Profiles
5.1 Astellas Pharma Inc.
5.1.1 Business Overview
Table 27: Astellas Pharma Sales by Business Segments (2018)
5.1.2 Financial Overview
Table 28: Astellas Pharma Sales and Net Income (2014-2018)
5.1.3 Business Strategies
Table 29: Astellas Pharma Major Product Approvals & Launches (2018)
5.2 Hisamitsu Pharmaceutical Co., Inc.
5.2.1 Business Overview
Table 30: Hisamitsu Pharmaceutical Sales by Business Segments (2018)
5.2.2 Financial Overview
Table 31: Hisamitsu Pharma Net Sales and Net Income (2014-2018)
5.2.3 Business Strategies
Table 32: Hisamitsu Pharmaceutical Research & Development Expenditure (2014-2018)
Table 33: Hisamitsu Pharmaceutical Product Approvals (2018)
5.3 Pfizer Inc.
5.3.1 Business Overview
Table 34: Major Business Segments of the Pfizer Inc. (2017)
Table 35: Pfizer Inc.'s Revenue Share by Major Business Segment (2017)
5.3.2 Financial Overview
Table 36: Pfizer Inc.’s Revenue and Net Income (2013-2017)
5.3.3 Business Strategies
Table 37: Pfizer Inc. R&D Expenses (2015-2017)
Table 38: Pfizer Major Agreements (2018)
5.4 Allergan Plc.
5.4.1 Business Overview
Table 39: Allergan Plc Net Revenues by Business Segments (2017)
5.4.2 Financial Overview
Table 40: Allergan Plc Net Revenues and Net Income (Loss) (2013-2017)
5.4.3 Business Strategies
Table 41: Allergan Plc Research and Development Expenditures (2015-2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report